Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotus Tissue Repair secures $26M series A funds

This article was originally published in Scrip

Executive Summary

Lotus Tissue Repair, founded in 2011 to focus on wound healing indications, has raised $26 million in a series A round led by Third Rock Ventures. Proceeds of the round will be used to advance the development of recombinant collagen type VII (rc7) technology which the company has licensed exclusively from the University of Southern California laboratory of scientific co-founders Dr Mei Chen and Dr David Woodley.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel